PLx Pharma Inc. Demonstrates Bioequivalence with Aspirin and PL 2100 -- Aspirin-PC

HOUSTON--(BUSINESS WIRE)--PLx Pharma Inc. announced today that it has successfully completed a clinical trial of PL 2100, also known as Aspirin-PC and demonstrated its bioequivalence with regular aspirin. This trial demonstrates PL 2100 Aspirin-PC may bridge to the safety and efficacy of aspirin for prescription (Rx) treatment and prevention of secondary prevention of stroke and myocardial infarction and over-the-counter (OTC) analgesic and fever indications.